



CORRESPONDENCE OPEN ACCESS

Beyond the Usual Suspects: RSV Infection in Patients With Hematological Malignancies Compared to Influenza and SARS-COV-2—A Report From the EPICOVIDEHA/EPIRESEHA Registry

Jon Salmanton-García^{1,2,3,4} | Francesco Marchesi⁵ | Milan Navrátil^{6,7} | Iker Falces-Romero^{8,9} | Maria Ilaria Del Principe¹⁰ | Jorge Labrador^{11,12} | Klára Piukovics¹³ | Verena Petzer¹⁴ | Monika M. Biernat^{15,16} | Michail Samarkos¹⁷ | Dario Leotta¹⁸ | Nicola Fracchiolla¹⁹ | Anna Dąbrowska-Iwanicka²⁰ | Antonio Vena²¹ | Benjamín Višek²² | Yavuz M. Bilgin²³ | Jens Van Praet²⁴ | Mario Virgilio Papa²⁵ | Inmaculada Heras Fernando²⁶ | Francesca Farina²⁷ | Luboš Drgoňa²⁸ | Josip Batinić^{29,30,31} | Barbora Weinbergerová³² | Nurettin Erben³³ | Joanna Drozd-Sokołowska³⁴ | Patricia García-Ramírez³⁵ | Annarosa Cuccaro³⁶ | Martin Čerňan³⁷ | Nicola Sgherza³⁸ | Tobias Lahmer³⁹ | Donald C. Vinh⁴⁰ | Gaëtan Planteveve⁴¹ | Alberto López-García⁴² | Chiara Cattaneo⁴³ | Nikola Pantić⁴⁴ | Sofya Khostelidi⁴⁵ | Julio Dávila-Valls⁴⁶ | Andrés Soto-Silva⁴⁷ | László Imre Pinczés⁴⁸ | Ferenc Magyari⁴⁸ | Reham Abdelaziz Khedr⁴⁸ | Michelina Dargenio⁴⁹ | Martijn Bakker⁵⁰ | Igor Stoma⁵¹ | Carolina Garcia-Vidal⁵² | Ildefonso Espigado⁵³ | Claudio Cerchione⁵⁴ | Caterina Buquicchio⁵⁵ | Zlate Stojanowski⁵⁶ | Gabriele Magliano⁵⁷ | Stefanie K. Gräfe⁵⁸ | Avinash Aujayeb^{1,2,3,4,59} | Lucia Prezioso⁶⁰ | Vladimir Otašević⁶¹ | Maria Merelli⁴⁴ | Erica Mackenzie⁶² | Andreas Glenthøj⁶³ | Eleni Gavriilaki⁶⁴ | Noha Eisa^{65,66} | Mario Delia^{67,68} | Alessandro Busca³⁸ | Ahlam Almasari⁶⁹ | Tatjana Adžić-Vukičević⁶⁸ | Ivana Urošević⁴⁴ | Uluhan Sili⁷⁰ | Carolina Miranda-Castillo⁷¹ | Gustavo-Adolfo Méndez⁷² | Stef Meers⁷³ | Monia Marchetti⁷⁴ | Nicola Coppola⁷⁵ | Gökçe Melis Çolak⁷⁶ | Darko Antić⁷¹ | Ditte Stampe Hersby^{44,77} | Pellegrino Musto⁶⁴ | Milche Cvetanoski^{38,78} | Martin Schönlein⁵⁷ | Tommaso Francesco Aiello⁷⁹ | Elena Arellano⁸⁰ | Davide Nappi⁵⁴ | Sonia Martín-Pérez⁵⁵ | Mirjana Mitrović⁴⁶ | Raul Cordoba^{44,77} | Romane Prin⁴² | Marta Callejas-Charavia⁸¹ | Gina Varricchio³⁵ | Martina Bavastro²⁵ | Alessandro Limongelli⁸² | Amalia N. Anastasopoulou⁸² | Alessandra Romano¹⁷ | Dominik Wolf¹⁸ | Kevin Nguyen¹⁴ | Lukas Van Den Ven^{1,2,3,4} | Alessia Di Pilla^{1,2,3,4} | Antonio Giordano^{83,84} | Oliver A. Cornely^{83,84} | Livio Pagano^{2,3,4,83,84,85}

Correspondence: Jon Salmanton-García (jon.salmanton-garcia@uk-koeln.de)

Received: 22 July 2025 | **Revised:** 30 October 2025 | **Accepted:** 10 November 2025

Keywords: hematological malignancy | neglected | opportunistic infection | real-world data | respiratory syncytial virus

To the Editor,

Respiratory syncytial virus (RSV) is a major cause of acute respiratory infections and seasonal hospitalisations, particularly among immunocompromised adults [1]. In patients with hematological malignancies, RSV can cause severe complications, including pneumonia, respiratory failure, and death, especially in those with lymphopenia, recent HSCT, or comorbidities [2]. Although antivirals, monoclonal antibodies, and vaccines exist for other high-risk groups, their efficacy in this population

remains uncertain [3]. Screening and diagnostic protocols are inconsistent, treatments are often empiric, and hematological patients are largely excluded from clinical trials. Moreover, comparative data versus influenza and SARS-CoV-2 are limited, impeding the development of targeted, evidence-based prevention and management strategies for this vulnerable group [4].

This study used the EPICOVIDEHA/EPIRESEHA registry [5] to describe RSV infection in adults with hematological malignancies

Oliver A. Cornely and Livio Pagano shared senior authorship.

For affiliations refer to page 374.

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial-NoDerivs](https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2025 The Author(s). *American Journal of Hematology* published by Wiley Periodicals LLC.

(Jan 2023–Dec 2024), comparing it with influenza and SARS-CoV-2. Data were collected via the international registry (NCT04733729), with ethical approval from Fondazione Policlinico Gemelli (ID 3226); consent was waived due to anonymization.

Eligible participants were adults (≥ 18 years) with laboratory-confirmed RSV and active hematological malignancy treatment within the past 5 years. Exclusions were benign hematologic conditions, solid tumors, age < 18 , treatment-free > 5 years, or RSV diagnosis based only on imaging (Figure S1). Collected data included demographics, malignancy type/status, recent therapy, RSV diagnostics, clinical presentation, infection severity, antivirals, hospitalization, prior-year RSV vaccination, and survival. Malignancy was classified as controlled (partial/complete remission) or active (stable, refractory, newly diagnosed). Infection severity was categorized as asymptomatic, mild, severe, or critical. Asymptomatic cases were defined as patients without symptoms at onset who remained at home. Mild cases included those presenting with extra-pulmonary symptoms managed at home, or patients who were asymptomatic at onset but required hospitalization. Severe disease was defined by the presence of pulmonary symptoms (such as cough, dyspnea, or sputum production) regardless of setting, or by hospitalization with any non-respiratory symptom. Critical disease encompassed all cases requiring ICU admission, irrespective of symptoms at onset. Data were reviewed by hematology and infectious disease specialists; incomplete or inconsistent records were excluded.

Two matching analyses were conducted—RSV versus influenza and RSV versus SARS-CoV-2—matching for age (± 10 years), viral season, and malignancy type/status; sex was matched when feasible. Categorical variables are counts/percentages, continuous variables as medians with IQR and absolute ranges. Fisher's exact or chi-square tests compared categorical data; Mann-Whitney U tests for continuous variables. Survival was assessed via Kaplan-Meier estimates with log-rank tests. Univariable Cox regression identified mortality predictors, with variables $p \leq 0.1$ entered into multivariable Cox regression using backward elimination. Hazard ratios (HR) with 95% confidence intervals (CI) were reported. Predictors included demographics, malignancy subtype/status, comorbidities, recent therapies (chemotherapy, immunotherapy, targeted therapy, HSCT, CAR-T, or none), co-infections, symptom burden, infection severity, antiviral use, secondary infections, and care setting. Analyses were performed in SPSS v25.0; significance set at $p \leq 0.05$.

Between January 2023 and December 2024, 243 patients with confirmed RSV infection were evaluated. Male predominance was observed ($n = 140$, 57.6%), with median age 64 years (IQR 52–73; range 18–93) (Table 1). Geographical distribution is in Table S1.

Lymphoma ($n = 63$, 25.9%) and plasma cell disorders ($n = 60$, 24.7%) were most prevalent. Hematological malignancy was controlled in 48.1% ($n = 117$). Up to 30.0% ($n = 73$) had ≥ 2 comorbidities, most often chronic cardiopathy ($n = 93$, 38.3%) and diabetes mellitus ($n = 33$, 13.6%). Neutrophils $\geq 1000/\mu\text{L}$ and lymphocytes $\geq 500/\mu\text{L}$ were seen in 65.8% ($n = 160$) and 56.0% ($n = 136$) of patients. Immunochemotherapy ($n = 74$, 30.5%) and conventional chemotherapy ($n = 45$, 18.5%) were common recent treatments (Table 1).

RSV was the sole pathogen in 88.5% ($n = 215$), with coinfections reported mainly with SARS-CoV-2 ($n = 14$, 5.9%). At RSV infection onset, 59.3% ($n = 114$) of patients had extra-pulmonary symptoms, 34.2% ($n = 83$) had pulmonary involvement, and 6.6% ($n = 16$) were asymptomatic. The most frequently reported symptoms were cough ($n = 182$; 75.2%) and fever ($n = 137$; 56.6%), followed by rhinorrhea ($n = 54$; 22.3%), respiratory distress ($n = 49$; 20.2%), and radiographic lung impairment ($n = 46$; 19.0%). Severe disease occurred in 63.8% ($n = 155$), and 27.2% ($n = 66$) were classified as mild. Hospital admission was required in 182 patients (74.9%), with a median stay of 14 days (IQR 7–26; range 1–119). ICU admission was necessary for 21 (8.6%), with a median ICU stay of 8 days (IQR 5–13; range 2–28). Specific antiviral therapy was administered in 17.7% ($n = 43$); most ($n = 154$, 63.4%) received supportive care. Secondary infections were mainly bacterial ($n = 44$, 18.1%) (Table 1).

The 30-day mortality rate was 6.2% ($n = 15$), with causes including hematological malignancy alone ($n = 4$, 1.6%), combined with RSV ($n = 6$, 2.5%), or RSV alone ($n = 3$, 1.2%). Mortality was significantly associated with fungal infections (aHR 5.059; 95% CI: 1.583–16.166; $p = 0.006$) and bacterial infections (aHR 3.264; 95% CI: 1.089–9.784; $p = 0.035$) (Tables 1 and S2).

RSV vs. influenza comparison ($n = 178$ each) showed key differences: influenza patients were more often vaccinated (11.2% vs. 0.6%; $p < 0.001$), had more chronic cardiopathy (52.2% vs. 38.2%; $p = 0.010$), and fever (57.9% vs. 73.0%; $p = 0.004$) and received more antivirals (82.0% vs. 15.2%; $p < 0.001$). RSV patients more frequently received immunoglobulins/corticosteroids (16.9%) and had more bacterial (21.3% vs. 12.4%; $p = 0.033$) and viral (5.6% vs. 1.1%; $p = 0.035$) secondary infections. RSV cases spent fewer days in intermediate care (median 5 vs. 12; $p = 0.010$) (Table 1).

RSV vs. SARS-CoV-2 comparison ($n = 203$ each): SARS-CoV-2 patients were more often vaccinated (9.4% vs. 0.5%; $p < 0.001$). RSV patients had fewer asymptomatic infections (7.4% vs. 18.2%) but presented more often with pulmonary involvement (33.0% vs. 19.2%; $p < 0.001$). Compared with SARS-CoV-2, RSV cases demonstrated significantly higher frequencies of cough (74.9% vs. 41.4%; $p < 0.001$), lung impairment (17.7% vs. 7.9%; $p = 0.007$), and respiratory distress (20.7% vs. 9.4%; $p = 0.003$), as well as higher rates of severe disease (62.1% vs. 40.4%; $p < 0.001$) and hospitalization (74.4% vs. 54.2%; $p < 0.001$). Treatment differed: SARS-CoV-2 patients received more antivirals/corticosteroids (68.5% vs. 14.3%), while most RSV patients received none (69.0% vs. 27.1%; $p < 0.001$) (Table 1).

No significant differences in 30-day survival were observed among RSV, influenza, and SARS-CoV-2 patients (Figure 1).

Our multicenter observational study of 243 patients with hematological malignancies and RSV infection offers new insights into the clinical presentation and therapeutic challenges of RSV in this population. By comparing RSV with influenza and SARS-CoV-2, we identified distinct clinical patterns and highlighted several unmet needs that are critical for improving care.

Lymphoid neoplasms—especially lymphoma and plasma cell disorders—were most common, reflecting known susceptibility

TABLE 1 | Clinical description of RSV cases and subsequent comparison with influenza and SARS-CoV-2 patients.

	RSV			RSV vs. influenza			RSV vs. SARS-CoV-2		
	RSV			Influenza			SARS-CoV-2		
	<i>n</i>	%		<i>n</i>	%	<i>p</i>	<i>n</i>	%	<i>p</i>
Sex						0.275			
Female	103	42.4		62	34.8		73	41.0	
Male	140	57.6		116	65.2		105	59.0	
Age, median (<i>IQR</i>) [range]	64 (52–73) [18–93]			63 (54–72) [19–86]			63 (54–71) [18–87]		
Underlying malignancy						0.820	63 (53–71) [18–91]		0.971
Lymphoma	63	25.9		51	28.7		55	27.1	
Plasma cell disorders	60	24.7		46	25.8		51	25.1	
Acute myeloid leukemia	48	19.8		43	24.2		45	22.2	
Chronic lymphocytic leukemia	20	8.2		11	6.2		13	6.4	
Acute lymphoblastic leukemia	24	9.9		16	9.0		21	10.3	
Myelodysplastic syndrome	12	4.9		6	3.4		9	4.4	
Chronic myeloid malignancies	11	4.5		4	2.2		8	3.9	
Aplastic anemia	5	2.1		1	0.6		1	0.5	
Status underlying malignancy at infection onset						—			—
Controlled malignancy	117	48.1		85	47.8		96	47.3	
Active malignancy	126	51.9		93	52.2		107	52.7	

(Continues)

TABLE 1 | (Continued)

	RSV vs. influenza				RSV vs. SARS-CoV-2			
	Influenza		RSV		SARS-CoV-2		RSV	
	n	%	n	%	n	%	n	%
Vaccination ≤ 365 days before infection								
Not vaccinated	239	98.4	158	88.8	177	99.4	184	90.6
Influenza	0	0.0	20	11.2	0	0.0	0	0.0
RSV	4	1.6	0	0.0	1	0.6	0	0.0
SARS-CoV-2	0	0.0	0	0.0	0	0.0	1	0.5
Comorbidities at infection onset								
0–1	170	70.0	119	66.9	126	70.8	138	68.0
2+	73	30.0	59	33.1	52	29.2	65	32.0
Chronic cardiopathy	93	38.3	93	52.2	68	38.2	87	42.9
Chronic pulmonary disease	31	12.8	24	13.5	22	12.4	26	12.8
Diabetes mellitus	33	13.6	25	14.0	26	14.6	28	13.8
Liver disease	12	4.9	12	6.7	8	4.5	7	3.4
Obesity	15	6.2	12	6.7	11	6.2	10	4.9
Renal impairment	21	8.6	6	3.4	13	7.3	21	10.3
Smoking history	25	10.3	24	13.5	20	11.2	25	12.3
Neutrophils at infection onset								
< 500	31	12.8	21	11.8	26	14.6	16	7.9
500–999	22	9.1	20	11.2	17	9.6	10	4.9
≥ 1000	160	65.8	118	66.3	113	63.5	137	67.5

(Continues)

TABLE 1 | (Continued)

	RSV vs. influenza						RSV vs. SARS-CoV-2					
	RSV			Influenza			RSV			SARS-CoV-2		
	n	%		n	%		n	%		n	%	p
Lymphocytes at infection onset												0.155
≤200	37	15.2	28	15.7	29	16.3	20	9.9	30	14.8		
201–499	42	17.3	37	20.8	33	18.5	26	12.8	37	18.2		
≥ 500	136	56.0	96	53.9	95	53.4	119	58.6	111	54.7		
Last chemotherapy before infection												—
Conventional chemotherapy	45	18.5	40	22.5	33	18.5	39	19.2	40	19.7		
Demethylating agents	9	3.7	20	11.2	9	5.1	6	3.0	9	4.4		
Immuno-chemotherapy	74	30.5	69	38.8	57	32.0	72	35.5	64	31.5		
Targeted therapy	34	14.0	19	10.7	25	14.0	31	15.3	30	14.8		
alloHSCT	41	16.9	11	6.2	28	15.7	19	9.4	32	15.8		
autoHSCT	11	4.5	5	2.8	9	5.1	10	4.9	9	4.4		
CAR-T	3	1.2	2	1.1	3	1.7	3	1.5	3	1.5		
No treatment	22	9.1	9	5.1	10	5.6	20	9.9	12	5.9		
Supportive measures	4	1.6	3	1.7	4	2.2	3	1.5	4	2.0		
Infection diagnosis season												—
Winter 2023	50	20.6	24	13.5	24	13.5	38	18.7	38	18.7		
Interseason 2023	2	0.8	1	0.6	1	0.6	2	1.0	2	1.0		
Autumn 2023 to Winter 2024	175	72.0	148	83.1	148	83.1	153	75.4	153	75.4		
Interseason 2024	3	1.2	0	0.0	0	0.0	2	1.0	2	1.0		
Autumn 2024	9	3.7	5	2.8	5	2.8	6	3.0	6	3.0		

(Continues)

TABLE 1 | (Continued)

	RSV vs. influenza				RSV vs. SARS-CoV-2			
	Influenza		RSV		SARS-CoV-2		RSV	
	<i>n</i>	%	<i>n</i>	%	<i>n</i>	%	<i>n</i>	<i>p</i>
Pathogen								—
Influenza	0	0.0	178	100.0	0	0.0	0	0.0
RSV alone	216	88.9	0	0.0	178	100.0	203	100.0
RSV in coinfection ^a	22	11.1	0	0.0	0	0.0	0	0.0
SARS-CoV-2	0	0.0	0	0.0	0	0.0	203	100.0
Symptoms at infection onset								
Main symptoms								
Cough	182	75.2	126	70.8	135	75.8	84	41.4
Fever	137	56.6	130	73.0	103	57.9	95	46.8
Rhinorrea	54	22.3	25	14.0	37	20.8	41	20.2
Lung impairment	46	19.0	27	15.2	33	18.5	16	7.9
Respiratory distress	49	20.2	34	19.1	36	20.2	19	9.4
Summarized								
No symptoms	16	6.6	5	2.8	9	5.1	37	18.2
Only non-pulmonary symptoms	144	59.3	122	68.5	110	61.8	127	62.6
At least pulmonary symptoms	83	34.2	51	28.7	59	33.1	39	19.2
Infection severity								
Asymptomatic	1	0.4	2	1.1	0	0.0	18	8.9
Mild	66	27.2	42	23.6	47	26.4	89	43.8
Severe	155	63.8	111	62.4	116	65.2	82	40.4
Critical	21	8.6	23	12.9	15	8.4	14	6.9
Stay during infection								
								<0.001

(Continues)

TABLE 1 | (Continued)

	RSV vs. influenza						RSV vs. SARS-CoV-2					
	RSV			Influenza			RSV			SARS-CoV-2		
	n	%		n	%		n	%		n	%	p
Home	61	25.1		42	23.6		42	23.6		93	45.8	25.6
Hospital	161	66.3		113	63.5		121	68.0		96	47.3	66.0
Overall days in hospital, median (IQR) [range]	14 (7–26) [1–119]			13 (5–23) [1–128]			14 (6–26) [1–119]			19 (7–31) [1–126]		0.121
Overall days in normal ward, median (IQR) [range]	14 (7–26) [1–119]			10 (5–21) [1–128]			13.5 (6–26) [1–119]			15.5 (7–30) [1–82]		0.403
Overall days in intermediate care, median (IQR) [range]	7 (4–24) [3–38]			12 (3–19) [1–37]			5 (3–24) [3–24]			12.5 (9–28) [5–56]		0.078
Hospital, ICU	21	8.6		23	12.9		15	8.4		14	6.9	8.4
No mechanical ventilation	3	1.2		4	2.2		2	1.1		5	2.5	0.242
Non-invasive	6	2.5		10	5.6		5	2.8		4	2.0	2.5
Invasive	12	4.9		9	5.1		8	4.5		5	2.5	4.9
Overall days in ICU, median (IQR) [range]	8 (5–13) [2–28]			9 (5–12) [1–30]			7 (5–13) [3–18]			10 (8–14) [3–32]		0.363
Infection treatment												<0.001
No treatment	154	63.4		28	15.7		121	68.0		55	27.1	69.0
Antivirals ± corticosteroids	43	17.7		146	82.0		27	15.2		139	68.5	14.3
Immunoglobulins	16	6.6		0	0.0		12	6.7		0	0.0	5.9
Corticosteroids	30	12.3		4	2.2		18	10.1		9	4.4	10.8
Secondary infections												
Bacterial	44	18.1		22	12.4		38	21.3		30	14.8	0.290
Fungal	14	5.8		5	2.8		11	6.2		7	3.4	0.348

(Continues)

TABLE 1 | (Continued)

	RSV vs. influenza			RSV vs. SARS-CoV-2		
	Influenza		RSV	SARS-CoV-2		RSV
	n	%	n	%	n	p
Other viral	16	6.6	2	1.1	10	5.6
Mortality, d30	15	6.2	14	7.9	10	5.6
Reason for mortality						
Hematological malignancy	4	1.6	2	1.1	4	2.2
Hematological malignancy, Virus	6	2.5	6	3.4	3	1.7
Virus	3	1.2	6	3.4	1	0.6
Other reasons	2	0.8	0	0.0	2	1.1

Abbreviations: alloHSCT, allogeneic hematopoietic stem cell transplantation; autoHSCT, autologous hematopoietic stem cell transplantation; CAR-T, chimeric antigen receptor T-cell therapy; CI, confidence interval; ICU, intensive care unit; IQR, interquartile range; n, number (sample size); RSV, respiratory syncytial virus; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

^aObserved RSV co-infections included: SARS-CoV-2 (n = 13 cases), influenza (n = 5), metapneumovirus and rhinovirus (n = 3, each), parainfluenza (n = 2), and rhinovirus and SARS-CoV-2 (n = 1).

of lymphoproliferative disorders to respiratory viruses due to impaired immunity and frequent use of B-cell-depleting therapies like rituximab and daratumumab [6], which hinder humoral responses and prolong infection vulnerability.

Over half of patients had active hematological malignancies at RSV diagnosis, likely contributing to the observed severity and high hospitalization rate. Active disease increases inflammatory burden, cumulative immunosuppression, and reduces functional status [7]. In line with existing literature [8], cardiovascular disease and diabetes—common comorbidities in this cohort—are independently linked to worse outcomes in respiratory viral infections, further amplifying RSV severity.

Neutropenia or lymphopenia at diagnosis occurred in only ~10% of patients, lower than in high-risk populations like acute leukemia or HSCT recipients [2]. This likely reflects the predominance of indolent lymphoid malignancies, where immune impairment is driven more by treatment and chronic immunosuppression than cytopenias. About half of the cohort had recent chemotherapy or immunochemotherapy, supporting the link between recent therapy and RSV severity, consistent with prior reports [2, 3].

RSV vaccination coverage was minimal, much lower than influenza and SARS-CoV-2, likely due to the recent availability of RSV vaccines and their exclusion from national or disease-specific guidelines. By contrast, established recommendations and routine use of influenza and SARS-CoV-2 vaccines likely explain their higher uptake.


Coinfections were rare, with SARS-CoV-2 most common, reflecting their co-circulation in hematological patients [2]. Asymptomatic RSV was uncommon; most initially had extrapulmonary symptoms, progressing to pulmonary involvement in approximately two-thirds, underscoring the need for close monitoring. In contrast, SARS-CoV-2 was often asymptomatic, likely due to broader testing, whereas RSV diagnosis remains largely symptom-driven and hospital-based, potentially delaying care.

Hospitalization occurred in 75% of cases, though ICU admission was rare, indicating that RSV often requires inpatient care but less frequently leads to critical illness. Despite generally milder symptoms than influenza, RSV caused more secondary infections—mainly bacterial—affecting ~20% of patients and significantly contributing to mortality, likely due to RSV-induced epithelial injury.

Antiviral treatment, primarily ribavirin, was administered in fewer than 20% of cases. This limited use reflects the lack of randomized trial data supporting its efficacy and the absence of treatment guidelines for non-transplant patients with hematological malignancies. In contrast, influenza was more frequently treated with oseltamivir, which has a stronger evidence base. While COVID-19 benefits from multiple validated antiviral options, treatment of RSV remains empirical and inconsistently applied.

All-cause mortality was ~6%, with RSV as a primary or contributing factor in most deaths. Fatal cases were largely linked to secondary infections, supporting the role of RSV-induced epithelial damage in facilitating bacterial and fungal superinfections [9]. The higher rate of bacterial co-infection observed in RSV

A) RSV vs influenza



B) RSV vs SARS-CoV-2




FIGURE 1 | Day 30 survival after infection diagnosis per pathogen.

compared with influenza may reflect several interrelated mechanisms. RSV is known to cause pronounced epithelial damage and impair mucociliary clearance, facilitating bacterial adherence and colonization of the lower respiratory tract. In addition, delayed diagnosis and the limited availability of specific antiviral or immunomodulatory therapies for RSV likely contribute

to prolonged viral replication and immune dysregulation, further predisposing patients to secondary bacterial infection. In contrast, influenza is more routinely diagnosed and promptly treated with established antivirals, which may mitigate the risk of bacterial superinfection. This finding underscores the importance of improving timely RSV diagnostics, expanding vaccine

coverage, and developing effective antivirals to prevent secondary infections and improve outcomes in this high-risk population. Although invasive fungal disease occurred in only 5%–6% of cases, it carried very high mortality, underscoring the need to consider and manage superinfections in RSV-infected patients with hematological malignancies.

The recent approval of RSV vaccines for older and immunocompromised adults is a major advance. Future studies should evaluate vaccine immunogenicity, safety, and effectiveness in patients with hematological malignancies, especially those on B-cell-depleting therapy [10]. Greater access to rapid and multiplex diagnostics could enable earlier detection, while clinical trials of new antivirals or combination therapies, as well as studies on prophylactic or pre-emptive strategies, are needed to guide future practice.

This study has several limitations, including its retrospective design, potential selection and reporting biases, incomplete or inconsistent RSV testing, lack of data on viral load, genotyping, and subtype, partial treatment information, and absence of immunological parameters, limiting assessment of host vulnerability.

RSV is a clinically significant respiratory infection in patients with hematological malignancies—especially those with active lymphoid neoplasms, recent chemotherapy, or coinfections—causing high hospitalization, secondary infection, and mortality rates. Compared with influenza and SARS-CoV-2, RSV remains underdiagnosed, undertreated, and under-vaccinated, highlighting the urgent need to improve vaccines, diagnostics, and therapies.

Author Contributions

J.S.-G., F.M., O.A.C., and L.P. contributed to study design and study supervision. J.S.-G. did the statistical plan and analysis. J.S.-G., F.M., O.A.C., and L.P. interpreted the data and wrote the paper. All the authors recruited and documented participants, critically read, reviewed, and agreed to publish the manuscript.

Funding

This study was funded by AstraZeneca GmbH (AstraZeneca Germany), which had no role in the design, data collection, analysis, interpretation, or writing of the manuscript.

Affiliations

¹Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany | ²Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Cologne, Germany | ³Department I of Internal Medicine, European Confederation for Medical Mycology (ECMM) Excellence Center, University of Cologne, Cologne, Germany | ⁴German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany | ⁵Hematology and Stem Cell Transplant Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy | ⁶Department of Haematology, University Hospital Ostrava, Ostrava, Czech Republic | ⁷Department of Haematology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic | ⁸Clinical Microbiology and Parasitology Department, Hospital Universitario La Paz, IdiPaz, Madrid, Spain | ⁹CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain | ¹⁰Hematology, Department of Biomedicine and

Prevention, University of Rome Tor Vergata, Rome, Italy | ¹¹Department of Hematology, Research Unit, Hospital Universitario de Burgos, Burgos, Spain | ¹²Facultad de Ciencias de la Salud, Universidad Isabel I, Burgos, Spain | ¹³Department of Internal Medicine, South Division Faculty of Medicine University of Szeged, Szeged, Hungary | ¹⁴Department of Hematology and Oncology, Comprehensive Cancer Center Innsbruck (CCCI), Medical University of Innsbruck (MUI), Austrian Comprehensive Cancer Network (ACCN), Innsbruck, Austria | ¹⁵Department of Haematology, Blood Neoplasms, and Bone Marrow Transplantation, Wroclaw, Poland | ¹⁶Medical University, Wroclaw, Poland | ¹⁷Laikon Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece | ¹⁸AOU Policlinico Rodolico San Marco, Catania, Italy | ¹⁹Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy | ²⁰Department of Lymphoid Malignancies, Maria Skłodowska-Curie National Research Institute of Oncology, Warszawa, Poland | ²¹IRCCS AOU San Martino (IRCCS Ospedale Policlinico San Martino), Genova, Italy | ²²University Hospital Hradec Králové, Hradec Králové, Czech Republic | ²³Department of Internal Medicine, ADRZ, Goes, the Netherlands | ²⁴Department of Nephrology and Infectious Diseases, AZ Sint-Jan Brugge AV, Brugge, Belgium | ²⁵Azienda Ospedaliera Sant'Anna e San Sebastiano, Caserta, Italy | ²⁶Hospital Morales Meseguer, Murcia, Spain | ²⁷Hematology and Bone Marrow Transplantation, IRCCS San Raffaele Scientific Institute, Milan, Italy | ²⁸Department of Oncohematology, Comenius University and National Cancer Institute, Bratislava, Slovakia | ²⁹Division of Hematology, Department of Internal Medicine, University Hospital Centre Zagreb, Zagreb, Croatia | ³⁰School of Medicine, University of Zagreb, Zagreb, Croatia | ³¹Croatian Cooperative Group for Hematological Diseases (KROHEM), Zagreb, Croatia | ³²Department of Internal Medicine – Hematology and Oncology, Masaryk University Hospital Brno, Brno, Czech Republic | ³³Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine Eskisehir Osmangazi University, Eskisehir, Turkey | ³⁴Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, Warsaw, Poland | ³⁵Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain | ³⁶Hematology Unit, Center for Translational Medicine, Azienda USL Toscana NordOvest, Livorno, Italy | ³⁷Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Olomouc, Czech Republic | ³⁸Hematology and Stem Cell Transplantation Unit, AOUC Policlinico, Bari, Italy | ³⁹Medizinische Klinik II, Klinikum rechts der Isar, TU München, Munich, Germany | ⁴⁰McGill University Health Centre, Montreal, Canada | ⁴¹Head ICU and CRC, Centre Hospitalier Victor DUPOUY, Argenteuil, France | ⁴²Fundacion Jimenez Diaz University Hospital, Health Research Institute IIS-FJD, Madrid, Spain | ⁴³Hematology Unit, ASST-Spedali Civili, Brescia, Italy | ⁴⁴Clinic of Hematology, University Clinical Center of Serbia, Belgrade, Serbia | ⁴⁵North-Western State Medical University Named After Iliá Ilich Méchnikov, Saint-Petersburg, Russia | ⁴⁶Hospital Nuestra Señora de Sonsoles, Ávila, Spain | ⁴⁷Faculty of Medicine, University of Chile, Infectious Diseases Unity, Salvador Hospital of Santiago, Santiago de Chile, Chile | ⁴⁸Division of Hematology, Department of Internal Medicine, University of Debrecen, Debrecen, Hungary | ⁴⁹Department of Pediatric Hematology/Oncology, National Cancer Institute-Cairo University, Children's Cancer Hospital, Cairo, Egypt | ⁵⁰Hematology and Stem Cell Transplant Unit, Lecce, Italy | ⁵¹University Medical Center Groningen, Groningen, the Netherlands | ⁵²Gomel State Medical University, Gomel, Belarus | ⁵³Hospital Clinic, Barcelona, Spain | ⁵⁴Department of Hematology, University Hospital Virgen Macarena – University Hospital Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS/CSIC), Universidad de Sevilla (Departamento de Medicina), Seville, Spain | ⁵⁵Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori' – IRST, Meldola, Italy | ⁵⁶Ematologia con Trapianto, Ospedale Dimecchi Barletta, Barletta, Italy | ⁵⁷University Clinic of Hematology, Skopje, Republic of North Macedonia | ⁵⁸ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy | ⁵⁹Universitätsklinikum Hamburg Eppendorf, Hamburg,

Germany | ⁶⁰Northumbria Healthcare, Newcastle, UK | ⁶¹Hospital University of Parma – Hematology and Bone Marrow Unit, Parma, Italy | ⁶²Azienda Sanitaria Universitaria del Friuli Centrale, Udine, Italy | ⁶³University of Kansas Medical Center, Kansas City, USA | ⁶⁴Department of Hematology, Copenhagen University Hospital – Rigshospitalet, Copenhagen, Denmark | ⁶⁵Hematology Department-BMT Unit, General Hospital of Thessaloniki ‘George Papanikolaou’, Thessaloniki, Greece | ⁶⁶2nd Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece | ⁶⁷Faculty of Medicine, Mansoura University, Mansoura, Egypt | ⁶⁸King Faisal Specialist Hospital, Jeddah, Saudi Arabia | ⁶⁹Stem Cell Transplant Center, AOU Citta’ della Salute e della Scienza, Turin, Italy | ⁷⁰Head of Clinic of Hematology, Clinical Center of Novi Sad, Novi Sad, Serbia | ⁷¹Department of Infectious Diseases and Clinical Microbiology, School of Medicine, Marmara University, Istanbul, Turkey | ⁷²Hospital Rey Juan Carlos, Móstoles, Spain | ⁷³Servicio de Infectología y Control de Infecciones, Hospital Escuela de Agudos Dr. Ramón Madariaga, Posadas, Misiones, Argentina | ⁷⁴AZ KLINA, Brasschaat, Belgium | ⁷⁵Hematology and Transplant Unit, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy | ⁷⁶Department of Mental Health and Public Medicine, University of Campania, Naples, Italy | ⁷⁷Faculty of Medicine, University of Belgrade, Belgrade, Serbia | ⁷⁸Department of Precision and Regenerative Medicine and Ionian Area, ‘Aldo Moro’ University School of Medicine, Bari, Italy | ⁷⁹Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany | ⁸⁰Department of Infectious Diseases, Hospital Clinic de Barcelona, University of Barcelona, IDIBAPS, Barcelona, Spain | ⁸¹CRA from CRC Centre Hospitalier Victor DUPOUY, Argenteuil, France | ⁸²Ospedale Policlinico San Martino, Genoa, Italy | ⁸³Hematology, Fondazione Policlinico Universitario Agostino Gemelli – IRCCS, Rome, Italy | ⁸⁴Hematology, Università Cattolica del Sacro Cuore, Rome, Italy | ⁸⁵Clinical Trials Centre Cologne (ZKS Köln), Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany

Acknowledgments

We would like to express our deepest gratitude to everyone who contributed to the development of this manuscript. In particular, we wish to pay special tribute to Dr. Alberto López-García. His dedication, knowledge, and unwavering support have been instrumental in advancing the EPICOVIDEHA/EPIRESEHA research since its inception. His legacy will endure through this work, and he will always be remembered with great appreciation and respect.

Ethics Statement

Ethical approval was granted by the institutional review board of Fondazione Policlinico Universitario Agostino Gemelli IRCCS in Rome (Study ID 3226), as well as by local ethics committees where applicable. Given the complete anonymization of patient data, the need for informed consent was waived in accordance with the specific requirements of participating institutions.

Conflicts of Interest

J.S.-G. has received payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing or educational events from Gilead, Menarini, and Pfizer; and has participated on a Data Safety Monitoring Board or Advisory Board for Pfizer, outside of the submitted work. O.A.C. has received grants or contracts from BMBF, Cidara, EU-DG RTD (101037867), F2G, Gilead, MedPace, MSD, Mundipharma, Octapharma, Pfizer, Scynexis; consulting fees from Abbvie, AiCuris, Biocon, Cidara, Gilead, IQVIA, Janssen, Matinas, MedPace, Menarini, Moderna, Molecular Partners, MSG-ERC, Noxxon, Octapharm, Pfizer, PSI, Scynexis, Seres; payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing or educational events from Abbott, Abbvie, Al-Jazeera Pharmaceuticals/Hikma, Gilead, Grupo Biotoscana/

United Medical/Knight, MedScape, MedUpdate, Merck/MSD, Noscendo, Pfizer, Shionogi, streamedup!; payment for expert testimony from Cidara; a German patent (“Geschlossene Inkubationssysteme mit verbessertem Atemwegszugang für Untersuchungsvorrichtungen,” DE 10 2021 113 007.7), filed by the University of Cologne and listing Oliver A. Cornely as one of three inventors; participation on a Data Safety Monitoring Board or Advisory Board from Boston Strategic Partners, Cidara, IQVIA, Janssen, MedPace, PSI, Pulmocide, Shionogi, The Prime Meridian Group; stock or stock options from CoRe Consulting, EasyRadiology; and other financial or non-financial interests from Wiley, outside of the submitted work. Other authors declare no competing interests related to the submitted work. All authors had full access to the data and had final responsibility for the decision to submit for publication.

Data Availability Statement

The corresponding author can provide the data supporting the findings of this study upon a reasonable request.

References

1. T. Shi, D. A. McAllister, K. L. O'Brien, et al., “Global, Regional, and National Disease Burden Estimates of Acute Lower Respiratory Infections due to Respiratory Syncytial Virus in Young Children in 2015: A Systematic Review and Modelling Study,” *Lancet* 390, no. 10098 (2017): 946–958.
2. S. Herrmann, S. Graefe, M. Christopeit, et al., “Respiratory Syncytial Virus Infection in Patients With Haematological Diseases: A Retrospective Multicentre Study,” *Infection* 53 (2025): 1341–1350.
3. F. Khawaja and R. F. Chemaly, “Respiratory Syncytial Virus in Hematopoietic Cell Transplant Recipients and Patients With Hematologic Malignancies,” *Haematologica* 104, no. 7 (2019): 1322–1331.
4. J. Salmanton-Garcia, F. Marchesi, M. Navratil, et al., “Respiratory Viruses in Patients With Hematological Malignancy in Boreal Autumn/Winter 2023–2024: EPICOVIDEHA-EPIFLUEHA Report,” *American Journal of Hematology* 100, no. 3 (2025): 358–374.
5. J. Salmanton-Garcia, F. Marchesi, F. Itri, et al., “Unveiling the Hidden Burden: From EPICOVIDEHA to EPIFLUEHA, Exploring the Epidemiology of Respiratory Viral Infections in Hematological Patients,” *Hema* 7, no. 11 (2023): e970.
6. M. S. Infante, J. Salmanton-Garcia, A. Fernandez-Cruz, et al., “B-Cell Malignancies Treated With Targeted Drugs and SARS-CoV-2 Infection: A European Hematology Association Survey (EPICOVIDEHA),” *Frontiers in Oncology* 12 (2022): 992137.
7. I. Ruiz-Camps and J. Aguilar-Company, “Risk of Infection Associated With Targeted Therapies for Solid Organ and Hematological Malignancies,” *Therapeutic Advances in Infectious Disease* 8 (2021).
8. N. Prasad, T. A. Walker, B. Waite, et al., “Respiratory Syncytial Virus-Associated Hospitalizations Among Adults With Chronic Medical Conditions,” *Clinical Infectious Diseases* 73, no. 1 (2021): e158–e163.
9. S. Manna, P. Baidara, and S. M. Mandal, “Molecular Pathogenesis of Secondary Bacterial Infection Associated to Viral Infections Including SARS-CoV-2,” *Journal of Infection and Public Health* 13, no. 10 (2020): 1397–1404.
10. M. Addo, O. Cornely, M. Denking, et al., “RSV Vaccination Strategies for High-Risk Patients 2023: A Collaborative Position Paper by Leading German Medical Societies and Organizations,” *Infection* 52, no. 1 (2024): 285–288.

Supporting Information

Additional supporting information can be found online in the Supporting Information section. **Data S1:** Supporting Information.